Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019?


Journal Article (Review)

Direct oral anticoagulants (DOACs) are now widely used for the management of venous thromboembolism (VTE) that now includes cancer-associated thrombosis. This review summarizes recent data on VTE prophylaxis and treatment, new challenges, guidelines, and updates as well as the current place for DOACs on the emerging cancer-associated VTE management landscape.

Full Text

Duke Authors

Cited Authors

  • Ramacciotti, E; Agati, LB; Caffaro, RA; Volpiani, GG; Lopes, RD; Comerota, AJ; Fareed, J

Published Date

  • January 2019

Published In

Volume / Issue

  • 25 /

Start / End Page

  • 1076029619856433 -

PubMed ID

  • 31234637

Pubmed Central ID

  • 31234637

Electronic International Standard Serial Number (EISSN)

  • 1938-2723

Digital Object Identifier (DOI)

  • 10.1177/1076029619856433


  • eng

Conference Location

  • United States